4-(3-chloropropylsulfonylamino)-1-benzylpiperidine | 863222-14-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3-chloropropylsulfonylamino)-1-benzylpiperidine
• 英文别名: N-(1-benzyl-4-piperidinyl)-3-chloro-1-propanesulfonamide；N-(1-benzylpiperidin-4-yl)-3-chloropropane-1-sulfonamide
• CAS: 863222-14-4
• 化学式: C₁₅H₂₃ClN₂O₂S
• 分子量: 330.879
• InChiKey: NSTVHCVUHYDBAS-UHFFFAOYSA-N

物化性质

• 沸点：
  456.9±55.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-chloropropylsulfonylamino)-1-benzylpiperidine 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 生成 1-benzyl-4-(1,1-dioxidoisothiazolidin-2-yl)piperidine
  参考文献：
  名称：

  Discovery of a Tetrahydropyrimidin-2(1H)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor

  摘要：

  Coagulation enzyme factor Xa (FXa) is a particularly promising target for the development of new anticoagulant agents. We previously reported the imidazo[1,5-c]imidazol-3-one derivative 1 as a potent and orally active FXa inhibitor. However, it was found that 1 predominantly undergoes hydrolysis upon incubation with human liver microsomes, and the human specific metabolic pathway made it difficult to predict the human pharmacokinetics. To address this issue, our synthetic efforts were focused on modification of the imidazo[1,5-c]imidazol-3-one moiety of the active metabolite 3a, derived from 1, which resulted in the discovery of the tetrahydropyrimidin-2(1H)-one derivative 5k as a highly potent and selective FXa inhibitor. Compound 5k showed no detectable amide bond cleavage in human liver microsomes, exhibited a good pharmacokinetic profile in monkeys, and had a potent antithrombotic efficacy in a rabbit model without prolongation of bleeding time. Compound 5k is currently under clinical development with the code name TAK-442.

  DOI：

  10.1021/jm901699j
• 作为产物：
  描述：

  4-氨基-1-苄基哌啶 、 3-氯丙烷磺酰氯 以 乙醚 为溶剂， 反应 3.0h， 以to give the title compound (678 mg)的产率得到4-(3-chloropropylsulfonylamino)-1-benzylpiperidine
  参考文献：
  名称：

  Novel Sulfone Amide Amide Derivatives

  摘要：

  本发明涉及通式（I）的化合物：其中A、B、C和D分别独立地是甲烷基团或氮原子，所述甲烷基团可选地具有至少一个取代基，其中E表示以下式（E1）所代表的基团：R1表示较低的烷基或芳基，可选地具有一个或多个取代基，或表示与E的任意可连接位置相连的较低的烷基烯基，以及其他。本发明的化合物可用作治疗与NPY相关的各种疾病的药剂。

  公开号：

  US20080161326A1

文献信息

• Sulfonamide derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07691860B2

  公开（公告）日：2010-04-06

  The present invention relates to compounds of the general formula (I): wherein A, B, C and D each independently are a methine group or a nitrogen atom, said methine group optionally having a substituent(s) with at least one of them meaning the methine group; E means a group represented by the following formulae (E1): R1 means a lower alkyl group or an aryl group optionally having a substituent(s) or means a lower alkylene group linked to arbitrary, linkable position(s) of E, and others. The compounds of the present invention are useful as an agent for the treatment of a variety of diseases related to NPY.

  本发明涉及一般式（I）的化合物：其中A、B、C和D各自独立地是一个甲基基团或氮原子，所述甲基基团可选择具有至少一个含义为甲基基团的取代基；E表示由以下式（E1）表示的基团：其中R1表示一个低碳基团或一个芳基团，可选择具有取代基，或表示连接到E的任意可连接位置的低碳基亚基，以及其他。本发明的化合物可用作治疗与NPY相关的各种疾病的药剂。
• NOVEL SULFONE AMIDE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1719765A1

  公开（公告）日：2006-11-08

  The present invention relates to compounds of the general formula (I): wherein A, B, C and D each independently are a methine group or a nitrogen atom, said methine group optionally having a substituent(s) with at least one of them meaning the methine group; E means a group represented by the following formulae (E1): R1 means a lower alkyl group or an aryl group optionally having a substituent(s) or means a lower alkylene group linked to arbitrary, linkable position(s) of E, and others. The compounds of the present invention are useful as an agent for the treatment of a variety of diseases related to NPY.

  本发明涉及通式 (I) 的化合物： 其中 A、B、C 和 D 各自独立地为一个甲基或一个氮原子，所述甲基可选择具有一个或多个取代基，其中至少一个取代基指甲基；E 指由下式（E1）代表的基团： R1 指一个低级烷基或一个芳基，可选择具有一个或多个取代基；或指一个低级亚烷基，与 E 的任意可连接位置相连；等等。 本发明的化合物可作为治疗与 NPY 有关的各种疾病的药物。
• EP1719765
  申请人：——

  公开号：——

  公开（公告）日：——
• US7691860B2
  申请人：——

  公开号：US7691860B2

  公开（公告）日：2010-04-06